Jingwu Xie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4155160/publications.pdf

Version: 2024-02-01

65 papers	4,977 citations	94433 37 h-index	106344 65 g-index
67 all docs	67 docs citations	67 times ranked	6170 citing authors

#	Article	IF	Citations
1	Regulation of pancreatic cancer metastasis through the Gli2-YAP1 axis via regulation of anoikis. Genes and Diseases, 2022, 9, 1427-1430.	3.4	3
2	Distinct transcriptomic landscapes of cutaneous basal cell carcinomas and squamous cell carcinomas. Genes and Diseases, 2021, 8, 181-192.	3.4	14
3	A critical role of AREG for bleomycin-induced skin fibrosis. Cell and Bioscience, 2021, 11, 40.	4.8	8
4	Prognosis and Characterization of Immune Microenvironment in Acute Myeloid Leukemia Through Identification of an Autophagy-Related Signature. Frontiers in Immunology, 2021, 12, 695865.	4.8	24
5	The Role of the Hedgehog Pathway in Chemoresistance of Gastrointestinal Cancers. Cells, 2021, 10, 2030.	4.1	16
6	The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer. Oncogene, 2019, 38, 1764-1777.	5.9	56
7	Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis. Cancers, 2018, 10, 403.	3.7	13
8	Functional significance of Hippo/YAP signaling for drug resistance in colorectal cancer. Molecular Carcinogenesis, 2018, 57, 1608-1615.	2.7	38
9	The role of GLI2 - ABCG2 signaling axis for 5Fu resistance in gastric cancer. Journal of Genetics and Genomics, 2017, 44, 375-383.	3.9	41
10	The role of GLI1 for 5-Fu resistance in colorectal cancer. Cell and Bioscience, 2017, 7, 17.	4.8	43
11	Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas. OncoTargets and Therapy, 2017, Volume 10, 1645-1653.	2.0	75
12	GLI1-mediated regulation of side population is responsible for drug resistance in gastric cancer. Oncotarget, 2017, 8, 27412-27427.	1.8	29
13	Identifying therapeutic targets in gastric cancer: the current status and future direction. Acta Biochimica Et Biophysica Sinica, 2016, 48, 90-96.	2.0	16
14	SHP2 phosphatase as a novel therapeutic target for melanoma treatment. Oncotarget, 2016, 7, 73817-73829.	1.8	41
15	The Impact of Genomic Profiling for Novel Cancer Therapy â€“ Recent Progress in Non-Small Cell Lung Cancer. Journal of Genetics and Genomics, 2016, 43, 3-10.	3.9	8
16	Deciphering the role of hedgehog signaling in pancreatic cancer. Journal of Biomedical Research, 2016, 30, 353.	1.6	54
17	Genetic Evidence for XPC-KRAS Interactions During Lung Cancer Development. Journal of Genetics and Genomics, 2015, 42, 589-596.	3.9	8
18	Pathways towards Precision Medicine in Cancer Management Using Genomic Information. Journal of Genetics and Genomics, 2015, 42, 515-516.	3.9	1

#	Article	IF	Citations
19	Longitudinal Bioluminescence Imaging of Primary Versus Abdominal Metastatic Tumor Growth in Orthotopic Pancreatic Tumor Models in NSG Mice. Pancreas, 2015, 44, 64-75.	1.1	9
20	Tissue Transglutaminase Mediated Tumorâ€“Stroma Interaction Promotes Pancreatic Cancer Progression. Clinical Cancer Research, 2015, 21, 4482-4493.	7.0	75
21	The Hedgehog pathway: role in cell differentiation, polarity and proliferation. Archives of Toxicology, 2015, 89, 179-191.	4.2	97
22	Promising molecular mechanisms responsible for gemcitabine resistance in cancer. Genes and Diseases, 2015, 2, 299-306.	3.4	106
23	Non-Canonical Hh Signaling in Cancerâ€"Current Understanding and Future Directions. Cancers, 2015, 7, 1684-1698.	3.7	54
24	The hedgehogâ€™s trick for escaping immunosurveillance. OncoImmunology, 2014, 3, e29180.	4.6	10
25	Defective TGF-Î² Signaling in Bone Marrowâ€“Derived Cells Prevents Hedgehog-Induced Skin Tumors. Cancer Research, 2014, 74, 471-483.	0.9	49
26	Combining Hedgehog Signaling Inhibition with Focal Irradiation on Reduction of Pancreatic Cancer Metastasis. Molecular Cancer Therapeutics, 2013, 12, 1038-1048.	4.1	49
27	Targeting hedgehog signaling in cancer: research and clinical developments. OncoTargets and Therapy, 2013, 6, 1425.	2.0	59
28	A Role for Transcription Factor STAT3 Signaling in Oncogene Smoothened-driven Carcinogenesis. Journal of Biological Chemistry, 2012, 287, 38356-38366.	3.4	29
29	Rab23 negatively regulates Gli1 transcriptional factor in a Su(Fu)-dependent manner. Cellular Signalling, 2012, 24, 1222-1228.	3.6	38
30	Increased risk of lung cancer associated with a functionally impaired polymorphic variant of the human DNA glycosylase NEIL2. DNA Repair, 2012, 11, 570-578.	2.8	42
31	Hedgehog signaling activation in the development of squamous cell carcinoma and adenocarcinoma of esophagus. International Journal of Biochemistry and Molecular Biology, 2012, 3, 46-57.	0.1	35
32	Clinical implications of hedgehog signaling pathway inhibitors. Chinese Journal of Cancer, 2011, 30, 13-26.	4.9	26
33	Hedgehog signaling in skin cancers. Cellular Signalling, 2011, 23, 1235-1243.	3.6	59
34	Expression of hedgehog signaling molecules in lung cancer. Acta Histochemica, 2011, 113, 564-569.	1.8	27
35	Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 Mutations in Thyroid Cancers. Endocrine Pathology, 2011, 22, 97-102.	9.0	33
36	Identification of Signature Genes for Detecting Hedgehog Pathway Activation in Esophageal Cancer. Pathology and Oncology Research, 2011, 17, 387-391.	1.9	12

#	Article	IF	Citations
37	Active sonic hedgehog signaling between androgen independent human prostate cancer cells and normal/benign but not cancerâ€associated prostate stromal cells. Prostate, 2011, 71, 1711-1722.	2.3	22
38	Tumor shrinkage by cyclopamine tartrate through inhibiting hedgehog signaling. Chinese Journal of Cancer, 2011, 30, 472-481.	4.9	17
39	Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers. International Journal of Biochemistry and Molecular Biology, 2011, 2, 89-98.	0.1	62
40	Identification of signature genes for detecting hedgehog signaling activation in gastric cancer. Molecular Medicine Reports, 2010, 3, 473-8.	2.4	3
41	Requirement of TGFÎ² Signaling for SMO-mediated Carcinogenesis. Journal of Biological Chemistry, 2010, 285, 36570-36576.	3.4	78
42	Protein Kinase CÎ´ Negatively Regulates Hedgehog Signaling by Inhibition of Gli1 Activity. Journal of Biological Chemistry, 2009, 284, 2150-2158.	3.4	37
43	MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle, 2009, 8, 2122-2124.	2.6	73
44	Hedgehog signaling pathway: Development of antagonists for cancer therapy. Current Oncology Reports, 2008, 10, 107-113.	4.0	44
45	Implications of hedgehog signaling antagonists for cancer therapy. Acta Biochimica Et Biophysica Sinica, 2008, 40, 670-680.	2.0	20
46	Regulatory Role of Human AP-Endonuclease (APE1/Ref-1) in YB-1-Mediated Activation of the Multidrug Resistance Gene MDR1. Molecular and Cellular Biology, 2008, 28, 7066-7080.	2.3	112
47	Oncogenic KRAS Activates Hedgehog Signaling Pathway in Pancreatic Cancer Cells. Journal of Biological Chemistry, 2007, 282, 14048-14055.	3.4	256
48	Loss of cell-adhesion molecule complexes in solid pseudopapillary tumor of pancreas. Modern Pathology, 2007, 20, 509-513.	5.5	57
49	Detoxification of olefinic epoxides and nucleotide excision repair of epoxide-mediated DNA damage: Insights from animal models examining human sensitivity to 1,3-butadiene. Chemico-Biological Interactions, 2007, 166, 226-231.	4.0	13
50	Suppressing Wnt Signaling by the Hedgehog Pathway through sFRP-1*. Journal of Biological Chemistry, 2006, 281, 35598-35602.	3.4	129
51	Activation of the hedgehog pathway in a subset of lung cancers. Cancer Letters, 2006, 244, 53-60.	7.2	51
52	Hedgehog signaling is activated in subsets of esophageal cancers. International Journal of Cancer, 2006, 118, 139-148.	5.1	138
53	Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis, 2006, 27, 1334-1340.	2.8	219
54	Regulation of Gli1 Localization by the cAMP/Protein Kinase A Signaling Axis through a Site Near the Nuclear Localization Signal*. Journal of Biological Chemistry, 2006, 281, 9-12.	3.4	110

#	Article	IF	Citations
55	Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis, 2005, 26, 1698-1705.	2.8	174
56	Identifying Biomarkers of Lung Cancer in the Post-Genomic Era. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2005, 3, 319-331.	0.3	2
57	Inhibition of Smoothened Signaling Prevents Ultraviolet B-Induced Basal Cell Carcinomas through Regulation of Fas Expression and Apoptosis. Cancer Research, 2004, 64, 7545-7552.	0.9	170
58	IFNÎ± induces Fas expression and apoptosis in hedgehog pathway activated BCC cells through inhibiting Ras-Erk signaling. Oncogene, 2004, 23, 1608-1617.	5.9	61
59	Novel mutations in the PATCHED gene in basal cell nevus syndrome. Molecular Genetics and Metabolism, 2002, 76, 57-61.	1.1	29
60	A frequent activated smoothened mutation in sporadic basal cell carcinomas. Oncogene, 1999, 18, 833-836.	5.9	188
61	Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature, 1998, 391, 90-92.	27.8	1,209
62	Identification of Mutations in the Human PATCHED Gene in Sporadic Basal Cell Carcinomas and in Patients with the Basal Cell Nevus Syndrome. Journal of Investigative Dermatology, 1998, 110, 885-888.	0.7	270
63	Identification of a large Myc-binding protein that contains RCC1-like repeats. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9172-9177.	7.1	125
64	Physical mapping of the 5 Mb D9S196-D9S180 interval harboring the basal cell nevus syndrome gene and localization of six genes in this region. Genes Chromosomes and Cancer, 1997, 18, 305-309.	2.8	10
65	Keratin expression during early embryonic development of Bufo bufo gargarizans. Cell Research, 1992, 2, 45-52.	12.0	1